Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Sane DC, Stump DC, Topol EJ, Sigmon KN, Clair WK, Kereiakes DJ, George BS, Stoddard MF, Bates ER, Stack RS, et al. Sane DC, et al. Circulation. 1991 Jan;83(1):170-5. doi: 10.1161/01.cir.83.1.170. Circulation. 1991. PMID: 1898641 Clinical Trial.
Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Harrington RA, Sane DC, Califf RM, Sigmon KN, Abbottsmith CW, Candela RJ, Lee KL, Topol EJ. Harrington RA, et al. Among authors: sane dc. J Am Coll Cardiol. 1994 Mar 15;23(4):891-8. doi: 10.1016/0735-1097(94)90634-3. J Am Coll Cardiol. 1994. PMID: 8106694 Free article. Clinical Trial.
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.
Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, Topol EJ, Califf RM. Berkowitz SD, et al. Among authors: sane dc. J Am Coll Cardiol. 1998 Aug;32(2):311-9. doi: 10.1016/s0735-1097(98)00252-6. J Am Coll Cardiol. 1998. PMID: 9708455 Free article. Clinical Trial.
Abciximab readministration: results of the ReoPro Readministration Registry.
Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, Cines DB, Jordan RE, Mascelli MA, Langrall MA, Damaraju L, Schantz A, Effron MB, Braden GA. Tcheng JE, et al. Among authors: sane dc. Circulation. 2001 Aug 21;104(8):870-5. doi: 10.1161/hc3301.094533. Circulation. 2001. PMID: 11514371 Clinical Trial.
Final results of the ReoPro readministration registry.
Dery JP, Braden GA, Lincoff AM, Kereiakes DJ, Browne K, Little T, George BS, Sane DC, Cines DB, Effron MB, Mascelli MA, Langrall MA, Damaraju L, Barnathan ES, Tcheng JE; ReoPro Readministration Registry Investigators. Dery JP, et al. Among authors: sane dc. Am J Cardiol. 2004 Apr 15;93(8):979-84. doi: 10.1016/j.amjcard.2003.12.051. Am J Cardiol. 2004. PMID: 15081439
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ. Steinhubl SR, et al. Among authors: sane dc. Circulation. 2001 May 29;103(21):2572-8. doi: 10.1161/01.cir.103.21.2572. Circulation. 2001. PMID: 11382726 Clinical Trial.
Clinical risks of thrombolytic therapy.
Califf RM, Fortin DF, Tenaglia AN, Sane DC. Califf RM, et al. Among authors: sane dc. Am J Cardiol. 1992 Jan 3;69(2):12A-20A. doi: 10.1016/0002-9149(92)91168-4. Am J Cardiol. 1992. PMID: 1729875 Review.
152 results